In a randomized, double-blind, placebo-controlled trial of men with early recurrent androgen-dependent prostate cancer, active cellular immunotherapy with sipuleucel-T (Provenge) failed to meet its primary endpoint for delaying time to biochemical failure.
In May, FDA made the controversial announcement that it required additional data before making a ruling on approval of sipuleucel-T, which remains investigational. The agency said it would accept either a positive interim or final analysis of survival from the ongoing IMPACT study to amend the biologics license application for the drug. Dendreon Corp., sipuleucel-T's manufacturer, said it expected to complete enrollment in IMPACT this year and anticipated interim survival results in 2008.
The ASCO study enrolled men with a rise in serum PSA as the only sign of disease recurrence after prostatectomy for localized disease. A total of 176 patients were randomized 2:1 to sipuleucel-T or placebo. The assigned treatment was administered every other week for a total of three doses beginning after a 3-month course of hormone ablation therapy.
Secondary endpoints for the study comprise time to confirmed biochemical failure (defined by a second confirmatory PSA ≥3.0 ng/mL measured 2 to 4 weeks after the first PSA ≥3.0 ng/mL), PSADT, time to metastasis, survival, toxicity, and measures of immune response. There was a trend favoring sipuleucel-T (HR=0.80) in the analysis of time to confirmed biochemical failure, and PSADT analyses showed statistically significant increases in the men treated with sipuleucel-T compared with controls.
Only 16% of men in the study (sipuleucel-T, 14.5%; placebo, 18.6%) have developed distant metastasis. Analysis of those results showed a trend in favor of sipuleucel-T for delaying distant failure (HR=0.73).
"While we are reporting the final analysis for time to biochemical failure, in this patient population, that endpoint is considered exploratory, rather than a direct measure of treatment benefit," said first author Tomasz M. Beer, MD, associate professor of medicine, division of hematology and medical oncology, Oregon Health & Science University Cancer Institute, Portland. "Time to distant failure is perhaps the most clinically relevant outcome measure for men with early recurrent prostate cancer, and the trend favoring sipuleucel-T is encouraging.
"However, because there were very few metastatic events so far, the benefit was not statistically significant. Follow-up is continuing, and additional analyses will be forthcoming for time to distant failure and survival."
PSADT increased
Analyses of PSADT showed significant differences favoring sipuleucel-T, whether PSADT was calculated from 30, 60, or 90 days following randomization to the time of biochemical failure. For all of those methods, PSADT was increased by about 35% in men treated with sipuleucel-T compared with placebo (~125 days vs. ~92 days). There was a 48% increase in PSADT comparing the immunotherapy group and controls in an analysis where PSADT was calculated after testosterone recovery (155 days vs. 105 days).
The men enrolled in the sipuleucel-T and placebo groups had similar demographic characteristics. Median age was 65 years, and most men (90%) were Caucasian and had a Gleason sum score of 7 (81%). Median PSA measured during the run-in period prior to hormone treatment was 2.2 ng/mL for the total population, and it decreased to 0.09 ng/mL after hormone ablation at the time of randomization to sipuleucel-T or placebo.
Study finds disparities in management of mCSPC
April 17th 2024“These findings suggest that guideline recommended treatment intensification remains low for patients with mCSPC in both Medicare and the Veterans Health Administration, but especially for Black patients,” says Daniel J. George, MD.